✦ LIBER ✦

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi

✍ Scribed by Merli, Francesco; Luminari, Stefano; Rossi, Giuseppe; Mammi, Caterina; Marcheselli, Luigi; Tucci, Alessandra; Ilariucci, Fiorella; Chiappella, Annalisa; Musso, Maurizio; Rocco, Alice Di; Stelitano, Caterina; Alvarez, Isabel; Baldini, Luca; Mazza, Patrizio; Salvi, Flavia; Arcari, Annalisa; Fragasso, Alberto; Gobbi, Paolo G.; Liberati, Anna Marina; Federico, Massimo

Book ID: 120486852
Publisher: Informa plc
Year: 2012
Tongue: English
Weight: 422 KB
Volume: 53
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428194.2011.621565

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost utility in the United States of rit

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma

✍ John C. Hornberger; Jennie H. Best 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

Safety and efficacy of cyclophosphamide,

Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial

✍ Josep-Maria Ribera; Albert Oriol; Mireia Morgades; Eva González-Barca; Pilar Mir 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

Combination of ibrutinib with rituximab,

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

✍ Younes, Anas; Thieblemont, Catherine; Morschhauser, Franck; Flinn, Ian; Friedber 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 305 KB

Efficacy and toxicity of 2 schedules of

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma : A randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA)

✍ Vincent Ribrag; Christian Gisselbrecht; Corinne Haioun; Gilles Salles; Jean-Bapt 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views